Vaxcyte
Most recent annual filing: 2026-02-24
- VAX-31 adult Ph3 topline4Q 2026VAX-31 adult Ph3 topline, 4Q 2026, thesis-defining
- VAX-31 infant Ph2 topline1H 2027VAX-31 infant Ph2 topline, 1H 2027, material
- VAX-31 adult readout1H 2027VAX-31 adult readout, 1H 2027, notable
- VAX-A1 Ph1 topline2H 2027VAX-A1 Ph1 topline, 2H 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
VAX-24
VAX-XL
VAX-A1
Protein Target: streptolysin O, C5a peptidase, SpyAD, Group A carbohydrate
VAX-GI
Technology platforms
XpressCF · Sutro Biopharma
Cell-free protein synthesis platform used to produce difficult-to-make proteins and antigens for high-fidelity vaccines; focus on bacterial disease prevention including pneumococcal, Group A Streptococcus, Shigella, Chlamydia, and other bacterial pathogens
Biotech Distilled coverage (2)
- 2026-08-06 UPDATE: Vaxcyte (PCVX) - The Factory Got Its Papers
- 2026-07-27 Vaxcyte (PCVX) — Scientific Deep Dive for VAX-31 and the PCV Franchise 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.